Release no 26/2010
Copenhagen and Oslo, 10th August, 2010
Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today
announced that the news release no. 25 of August 9th 2010 by mistake gave the
impression that Affitech aims for a New Drug Application in Russia and CIS for
AT001/r84 in 2011 based on the announced preclinical results with this drug
candidate. The right information is that the company aims for a Clinical Trial
Application for AT001/r84 in Russia and CIS in 2011.
--------------------------------------------------------------------------------
| For more information please contact Affitech A/S: |
--------------------------------------------------------------------------------
| Martin Welschof, Managing Director | Randi Krogsgaard, |
| | Corporate Communications |
| Tel # +47 95 12 81 37 | Tel # +45 2320 1001 |
| | e-mail: ir@affitech.com |
--------------------------------------------------------------------------------
Disclaimer
This news release contains forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
results of the financial condition and operations of Affitech A/S. There are
many factors that could cause actual results and developments to differ
materially from those expressed or implied by these forward-looking statements
and forecasts. These factors include, among other things, risks associated with
technological development, the risk that research & development will not yield
new products that achieve commercial success, the impact of competition, the
ability to transact viable and profitable commercial deals, the risk of
non-approval of patents not yet granted, and difficulties of obtaining relevant
governmental approvals for new products.
No expressed or implied representations or warranties are given concerning
Affitech A/S or the accuracy or completeness of the information provided herein,
and no claims shall be made by the recipient of this news release by virtue of
the information contained herein.
Affitech aims for a clinical trial application for AT001/r84 in Russia in 2011
| Source: Affitech A/S